CD274 and neoplasm: Furthermore, 89Zr-atezolizumab tumor uptake was highly correlated to patient response to atezolizumab as measured by RECIST categorization and Kaplan-Meier curves at a much more significant degree compared to two separate FDA-approved clinical IHC protocols for staining tumor tissues for PD-L1 (Figure 4C), strengthening the role that non-invasive imaging can play as a predictive and prognostic marker for anti-PD-L1 immunotherapy.